- Home
- MTN vs BPMC Comparison
MTN vs BPMC Comparison
Compare MTN & BPMC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTN
- BPMC
- Stock Information
- Founded
- MTN 1997
- BPMC 2008
- Country
- MTN United States
- BPMC United States
- Employees
- MTN N/A
- BPMC N/A
- Industry
- MTN Services-Misc. Amusement & Recreation
- BPMC Biotechnology: Pharmaceutical Preparations
- Sector
- MTN Consumer Discretionary
- BPMC Health Care
- Exchange
- MTN Nasdaq
- BPMC Nasdaq
- Market Cap
- MTN 7.1B
- BPMC 7.0B
- IPO Year
- MTN 1997
- BPMC 2015
- Fundamental
- Price
- MTN $158.54
- BPMC $92.25
- Analyst Decision
- MTN Hold
- BPMC Buy
- Analyst Count
- MTN 10
- BPMC 19
- Target Price
- MTN $204.30
- BPMC $123.61
- AVG Volume (30 Days)
- MTN 506.1K
- BPMC 1.0M
- Earning Date
- MTN 03-10-2025
- BPMC 02-13-2025
- Dividend Yield
- MTN 5.64%
- BPMC N/A
- EPS Growth
- MTN 5.26
- BPMC N/A
- EPS
- MTN 6.16
- BPMC N/A
- Revenue
- MTN $2,886,901,000.00
- BPMC $508,824,000.00
- Revenue This Year
- MTN $5.54
- BPMC $44.29
- Revenue Next Year
- MTN $4.20
- BPMC $32.49
- P/E Ratio
- MTN $25.72
- BPMC N/A
- Revenue Growth
- MTN 0.64
- BPMC 104.04
- 52 Week Low
- MTN $156.61
- BPMC $80.68
- 52 Week High
- MTN $236.64
- BPMC $121.90
- Technical
- Relative Strength Index (RSI)
- MTN 31.49
- BPMC 34.05
- Support Level
- MTN $164.56
- BPMC $90.84
- Resistance Level
- MTN $168.45
- BPMC $96.78
- Average True Range (ATR)
- MTN 3.34
- BPMC 4.34
- MACD
- MTN -0.48
- BPMC -2.26
- Stochastic Oscillator
- MTN 11.62
- BPMC 5.64
About MTN Vail Resorts Inc.
Vail Resorts Inc Bhd is a resorts and casinos company that operates mountain resorts and ski areas. The company has three business segments that include Mountain, Lodging, and Real Estate. The Mountain segment operates numerous ski resort properties that offer a variety of winter and summer activities, such as skiing, snowboarding, snowshoeing, hiking, and mountain biking. The Lodging segment owns and operates hotels and condominiums. The Real Estate segment owns, develops, and leases real estate, typically near its other properties. The company generates the vast majority of its revenue within the United States.
About BPMC Blueprint Medicines Corporation
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer.